EADV 2026 Preview: Emerging Dermatology Therapies and Competitive Trends
EADV 2026 at a glance At 2026,will differentiation in dermatology move beyond…
AI perception of JAK Inhibitors in Atopic Dermatitis | LucidScope AI Visibility Audit
Produced with LucidScope, part of the LucidQuest ecosystem. How AI systems…
Bionyra Pharma Launches With $165M to Advance Immunology Biologics | Lucid Diligence Brief
Bionyra Pharma launched with $165M to advance TL1A, IL-23 and IL-25 biologics…
AbbVie's Apogee Acquisition Valued at $10.9B. | Lucid Diligence Brief
AbbVie’s Apogee deal adds zumilokibart and asthma assets as immunology growth…
Immunology Today—June 24, 2026
This week’s Immunology update highlights regulatory approvals, advancing late-…
Immunology Today—June 17, 2026
This week’s Immunology update highlights regulatory progress, late-stage…
Immunology Today—June 3, 2026
This week’s Immunology update highlights regulatory and clinical developments…
EADV Symposium 2026 Preview: Emerging Dermatology Trends and AI
EADV Symposium at a glance EADV Symposium 2026 in Athens highlights emerging…
Immunology Today—April 29, 2026
This week’s Immunology update highlights regulatory actions, clinical progress,…
Immunology Today—April 22, 2026
This week’s Immunology update highlights regulatory progress, clinical pipeline…
Respiratory Today—April 17, 2026
This week’s Respiratory Research update highlights regulatory momentum,…